阿伐那非是一种高选择性的口服磷酸二酯酶5抑制剂。Ⅰ、Ⅱ、Ⅲ期临床试验显示阿伐那非治疗勃起功能障碍与其他磷酸二酯酶5抑制剂相比,具有起效迅速、持续作用时间短、不良反应更少的特点,且有良好的临床效果及安全性,2012年4月27日美国食品和药物管理局批准其治疗轻至重度的勃起功能障碍(ED)患者。本文将重点对阿伐那非治疗ED患者的药理学及临床评价等方面进行综述。 Avanafil is a highly selective oral phosphodiesterase 5 inhibitor. Phase Ⅰ, Ⅱ and Ⅲ clinical trials showed that atorvastatin treatment of erectile dysfunction compared with other phosphodiesterase 5 inhibitors, with rapid onset, duration of action is short, fewer adverse reactions, and have good Clinical Effectiveness and Safety, April 27, 2012 US Food and Drug Administration Approves Treatment for Patients with Light to Severe Erectile Dysfunction (ED). This article will focus on the treatment of atorvastatin in patients with ED pharmacological and clinical evaluation and other aspects are reviewed.